Triple-negative breast cancer is one of the most deadly forms of the disease, does not respond to hormonal therapies such as tamoxifen, or targeted drugs like Herceptin and nearly one quarter of patients diagnosed will not survive for more than five years.

Now researchers at Cambridge University and the Wellcome Trust’s Sanger Institute have found that the BCL11A gene is overactive in eight out of ten patients.

Or should we aspire to a world where inclusive services are the norm, and hence ‘unremarkable’? Dr Justin Lee, Research Fellow at the Institute of Policy Studies, discusses what it means to be a truly inclusive society.

"Women are referred to a gynaecologist at a higher facility; this is a major reason for loss to follow-up".  Dr. Suneeta Krishnan shares with PatientsEngage her findings and recommendations of the implementation science research project to promote the adoption and effective scale-up of cervical cancer prevention in India.

1. According to you, which screening method is the most cost-effective?